XML 32 R22.htm IDEA: XBRL DOCUMENT v3.19.1
Legal Settlements and Loss Contingencies
3 Months Ended
Mar. 31, 2019
Legal Settlements and Loss Contingencies
NOTE 15 – 
Legal Settlements and Loss Contingencies:
Legal settlements and loss contingencies for the first three months of 2019 
amounted to an expense
of $57 million, compared to an income of $1,278 million in the first three months of 2018. The income in the first quarter of 2018 consisted primarily of the working capital adjustment with Allergan, the Rimsa settlement and a reversal of the reserve related to the carvedilol
judgment.
As of March 31, 2019 and December 31, 2018, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses was $618 million and $562 million, respectively.